# Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

> **NCT04494503** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 123 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** APG-2575
- **DRUG:** Rituximab
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT04494503
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-31
- **Primary completion:** 2024-10-20
- **Final completion:** 2025-12
- **Target enrollment:** 123 (ESTIMATED)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04494503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04494503, "Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04494503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*